Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPU H71
Description: Potent Hsp90 inhibitor
Chemical Name: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine
Purity: ≥98% (HPLC)
Biological Activity for PU H71
PU H71 is a potent inhibitor of heat shock protein 90 (Hsp90) (IC50 = 51 nM in MDA-MB-468 cells). Also inhibits cell growth in a range of breast cancer cell lines (IC50 values are 17, 31, 65, 87 and 140 nM for SKBr3, MCF-7, MDA-MB-468, HCC-1806 and MDA-MB-231 cells respectively). Shown to inhibit cell proliferation and induce apoptosis in triple-negative breast cancer (TNBC) cells.
Technical Data for PU H71
| M. Wt | 512.37 |
| Formula | C18H21IN6O2S |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 873436-91-0 |
| PubChem ID | 9549213 |
| InChI Key | SUPVGFZUWFMATN-UHFFFAOYSA-N |
| Smiles | IC1=CC4=C(OCO4)C=C1SC3=NC2=C(N)N=CN=C2N3CCCNC(C)C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for PU H71
References for PU H71
References are publications that support the biological activity of the product.
He et al (2006) Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J.Med.Chem. 49 381 PMID: 16392823
Chan et al (2008) Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Res. 68 216 PMID: 18172314
Caldas-Lopes et al (2009) Hsp90 inhibitor, PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc.Natl.Acad.Sci.USA 106 8368 PMID: 19416831
View Related Products by Target
View Related Products by Product Action
Keywords: PU H71, PU H71 supplier, PUH71, heat, shock, proteins, hsp90, inhibitors, inhibits, potent, Hsp90, 3104, Tocris Bioscience
4 Citations for PU H71
Citations are publications that use Tocris products. Selected citations for PU H71 include:
Li et al (2016) PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy. J Radiat Res 57 572 PMID: 27242340
Lee et al (2016) The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining. Radiother Oncol 121 162 PMID: 27666928
Echeverría et al (2019) The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity. PLoS One 14 e0208287 PMID: 30726209
Orozco-Díaz et al (2019) The interaction between RE1-silencing transcription factor (REST) and heat shock protein 90 as new therapeutic target against Huntington's disease. PLoS One 14 e0220393 PMID: 31361762
Reviews for PU H71
There are currently no reviews for this product. Be the first to review PU H71 and earn rewards!
Have you used PU H71?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cell Cycle and DNA Damage Research Product Guide
This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:
- Cell Cycle and Mitosis
- DNA Damage Repair
- Targeted Protein Degradation
- Ubiquitin Proteasome Pathway
- Chemotherapy Targets
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.